VEETIDS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEETIDS (VEETIDS).
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
| Metabolism | Voretigene neparvovec is not metabolized by cytochrome P450 enzymes; it is a gene therapy vector expected to undergo intracellular processing and degradation. |
| Excretion | Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%. |
| Half-life | Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment. |
| Protein binding | 10-20% bound to albumin. |
| Volume of Distribution | 0.2-0.3 L/kg, indicating predominantly extracellular distribution. |
| Bioavailability | Oral: 90-95%; IM: 95-100%. |
| Onset of Action | IV: 5-10 minutes; IM: 15-30 minutes; Oral: 30-60 minutes. |
| Duration of Action | IV/IM: 6-8 hours; Oral: 4-6 hours; extended for renally impaired patients. |
500 mg orally twice daily for 7-14 days.
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl >= 50 mL/min: no adjustment; CrCl 30-49: 250 mg twice daily; CrCl 15-29: 250 mg once daily; CrCl < 15: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | For children >= 12 years: same as adult; for 6-11 years: 10 mg/kg twice daily, max 500 mg/dose; for 2-5 years: 10 mg/kg twice daily, max 250 mg/dose. |
| Geriatric use | No specific dose adjustment based solely on age; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VEETIDS (VEETIDS).
| Breastfeeding | Limited human data; small amounts excreted into breast milk (M/P ratio unknown). Caution recommended, monitor infant for drowsiness and poor feeding. |
| Teratogenic Risk | First trimester: Category C based on animal studies showing fetal developmental toxicity; avoid unless benefit outweighs risk. Second and third trimesters: Not associated with major teratogenic effects, but may cause fetal respiratory depression and withdrawal syndrome with chronic use. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to voretigene neparvovec or any excipients","Patients with active ocular infections"]
| Precautions | ["Risk of retinal structural abnormalities including retinal thinning and macular hole","Potential for immune responses to AAV capsid proteins","Possible need for systemic corticosteroids to manage ocular inflammation","Not recommended for patients with significant pre-existing retinal damage"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and respiratory function. Fetal heart rate monitoring during labor; assess neonatal withdrawal signs after chronic use. |
| Fertility Effects | No significant impact on fertility in animal studies; delayed implantation observed at high doses. Human data insufficient. |